| Carcinoma breast stage IV
Phesgo vs Arimidex
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Phesgo vs Arimidex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsArimidex has a higher rate of injection site reactions vs Phesgo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Arimidex but not Phesgo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Phesgo
Arimidex
At A Glance
SC injection
Every 3 weeks
HER2/neu receptor antagonist
Oral
Daily
Aromatase inhibitor
Indications
- HER2-positive carcinoma of breast
- Inflammatory Breast Carcinoma
- Locally advanced breast cancer
- Carcinoma breast stage IV
- Malignant neoplasm of breast
- Locally advanced breast cancer
- Carcinoma breast stage IV
Dosing
HER2-positive carcinoma of breast, Inflammatory Breast Carcinoma, Locally advanced breast cancer Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with chemotherapy; neoadjuvant: 3-6 preoperative cycles then continue to complete 18 total cycles; adjuvant: up to 18 cycles (1 year) starting Day 1 of first taxane-containing cycle.
Carcinoma breast stage IV Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with docetaxel until disease progression or unmanageable toxicity.
Malignant neoplasm of breast 1 mg tablet orally once daily; adjuvant treatment duration in the ATAC trial was 5 years.
Locally advanced breast cancer, Carcinoma breast stage IV 1 mg tablet orally once daily; continue until tumor progression.
Contraindications
- Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any excipient of PHESGO
- Hypersensitivity to anastrozole or any excipient (including anaphylaxis, angioedema, and urticaria)
Adverse Reactions
Most common (>=5%) Alopecia, nausea, diarrhea, anemia, asthenia, fatigue, stomatitis, myalgia, arthralgia, neutropenia, vomiting, constipation, headache, dysgeusia, decreased appetite, peripheral sensory neuropathy, mucosal inflammation, injection site reaction, radiation skin injury, insomnia, cough
Serious Febrile neutropenia, neutropenic sepsis, neutrophil count decreased, cardiomyopathy, pulmonary toxicity
Postmarketing Glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common (>=10%) Hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, lymphedema
Serious Skin lesions, ulcers, or blisters; severe allergic reactions with swelling of face, lips, tongue, and/or throat; liver function abnormalities including hepatitis
Postmarketing Hepatobiliary events (increases in alkaline phosphatase, ALT, AST, gamma-GT, and bilirubin; hepatitis), erythema multiforme, Stevens-Johnson syndrome, angioedema, urticaria, anaphylaxis, myalgia, hypercalcemia, tendon disorders including tendon rupture and tendonitis
Pharmacology
Pertuzumab blocks HER2 heterodimerization at subdomain II to inhibit MAP kinase and PI3K signaling, trastuzumab binds subdomain IV to inhibit HER2-mediated cell proliferation, and together they augment antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor cells; hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability and enable systemic absorption.
Anastrozole is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme, significantly lowering serum estradiol concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Phesgo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Arimidex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Phesgo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Arimidex
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Phesgo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Arimidex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PhesgoView full Phesgo profile
ArimidexView full Arimidex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.